Share on LinkedInShare on LinkedIn

ARTICLE · 08 SEPTEMBER 2021

PTAB Challenges To Orange Book-Listed And Biologic Patents

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The USPTO released an update to its PTAB Orange Book Patent/Biologic Patent Study on August 11, 2021.

United StatesIntellectual Property

The USPTO released an update to its PTAB Orange Book Patent/Biologic Patent Study on August 11, 2021. The initial study was released on March 13, 2018, and the second was released on July 18, 2019.  This report is the third issued by the USPTO to provide data on Orange Book-listed patents challenged in AIA post-grant proceedings, and the second with data on biologic patents. The data from these reports show that petitions challenging Orange Book-listed and biologic patents remain a small percentage of the overall number of petitions filed (see Fig. 1). These low percentages possibly reflect the perceived strength of these patents or parties' preferences for adjudicating patentability/validity in other forums, particularly in light of the special Hatch-Waxman and BPCIA litigation procedures.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from